NZ628943A - Human antibodies to clostridium difficile toxins - Google Patents

Human antibodies to clostridium difficile toxins

Info

Publication number
NZ628943A
NZ628943A NZ628943A NZ62894313A NZ628943A NZ 628943 A NZ628943 A NZ 628943A NZ 628943 A NZ628943 A NZ 628943A NZ 62894313 A NZ62894313 A NZ 62894313A NZ 628943 A NZ628943 A NZ 628943A
Authority
NZ
New Zealand
Prior art keywords
clostridium difficile
human antibodies
seq
amino acid
acid sequence
Prior art date
Application number
NZ628943A
Other languages
English (en)
Inventor
Anne Gurnett-Bander
Carlos Arrecubieta
Israel Lowy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ714516A priority Critical patent/NZ714516A/en
Publication of NZ628943A publication Critical patent/NZ628943A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NZ628943A 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins NZ628943A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ714516A NZ714516A (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605914P 2012-03-02 2012-03-02
US201261608255P 2012-03-08 2012-03-08
US201261717404P 2012-10-23 2012-10-23
PCT/US2013/028630 WO2013130981A1 (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Publications (1)

Publication Number Publication Date
NZ628943A true NZ628943A (en) 2016-08-26

Family

ID=47844536

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ628943A NZ628943A (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins
NZ714516A NZ714516A (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ714516A NZ714516A (en) 2012-03-02 2013-03-01 Human antibodies to clostridium difficile toxins

Country Status (18)

Country Link
US (2) US9399674B2 (enExample)
EP (1) EP2820044A1 (enExample)
JP (2) JP2015509962A (enExample)
KR (1) KR20140130709A (enExample)
CN (2) CN104203976A (enExample)
AR (1) AR090219A1 (enExample)
AU (1) AU2016203511A1 (enExample)
BR (1) BR112014021251A2 (enExample)
CA (1) CA2863536A1 (enExample)
HK (1) HK1200463A1 (enExample)
IL (1) IL233884A0 (enExample)
MX (1) MX2014010527A (enExample)
NZ (2) NZ628943A (enExample)
RU (2) RU2628305C2 (enExample)
SG (2) SG11201405087PA (enExample)
TW (1) TWI592422B (enExample)
UY (1) UY34652A (enExample)
WO (1) WO2013130981A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
ES2870506T3 (es) 2015-02-19 2021-10-27 Immune Biosolutions Inc Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
JP2018517670A (ja) * 2015-04-15 2018-07-05 メディミューン，エルエルシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）感染および関連疾患の治療方法
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3753952A4 (en) * 2017-12-13 2022-04-13 XDCExplorer (Shanghai) Co., Ltd. EGFRVIII ANTIBODY AND CONJUGATE, AND METHODS FOR ITS PRODUCTION AND USE
WO2020060771A1 (en) * 2018-09-18 2020-03-26 Vanderbilt University Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021219786A1 (en) 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5224657A (en) 1989-05-23 1993-07-06 Kabushiki Kaisha Toshiba Cryogenic refrigerator
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
JP4312259B2 (ja) * 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CN1809591A (zh) * 2003-05-21 2006-07-26 米德列斯公司 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
UA109105C2 (uk) * 2006-04-17 2015-07-27 Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
UA96768C2 (uk) * 2006-08-02 2011-12-12 Йоганес Гутенберг-Універсітет Майнц Лікарський засіб від lct-отруєнь
US8084684B2 (en) 2006-10-09 2011-12-27 Solexel, Inc. Three-dimensional thin-film solar cells
US20110020356A1 (en) 2007-12-07 2011-01-27 Lin Fang Therapeutic clostridium difficile antibody compositions
CA2714720A1 (en) 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to clostridium difficile spores and uses thereof
WO2010094970A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
PL2480255T3 (pl) * 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
WO2011063346A1 (en) 2009-11-20 2011-05-26 Northshore University Health System Research Institute Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体

Also Published As

Publication number Publication date
EP2820044A1 (en) 2015-01-07
CN108101983A (zh) 2018-06-01
CA2863536A1 (en) 2013-09-06
CN104203976A (zh) 2014-12-10
AU2013203942A1 (en) 2013-09-19
WO2013130981A1 (en) 2013-09-06
AR090219A1 (es) 2014-10-29
MX2014010527A (es) 2014-10-14
US9399674B2 (en) 2016-07-26
TWI592422B (zh) 2017-07-21
RU2017127772A (ru) 2019-02-04
AU2013203942B2 (en) 2016-03-10
UY34652A (es) 2013-09-02
HK1200463A1 (en) 2015-08-07
BR112014021251A2 (pt) 2017-06-27
KR20140130709A (ko) 2014-11-11
SG11201405087PA (en) 2014-09-26
IL233884A0 (en) 2014-09-30
SG10201610123UA (en) 2017-01-27
NZ714516A (en) 2017-06-30
JP2015509962A (ja) 2015-04-02
TW201350501A (zh) 2013-12-16
AU2013203942A8 (en) 2016-08-11
JP2018029625A (ja) 2018-03-01
RU2628305C2 (ru) 2017-08-15
AU2016203511A1 (en) 2016-06-16
RU2014139552A (ru) 2016-04-20
US20160264650A1 (en) 2016-09-15
US20130230531A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ603607A (en) Cgrp antibodies
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
EA035160B9 (ru) Антитела к st2 и их применение
NZ608660A (en) Anti-cd48 antibodies and uses thereof
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
MX389805B (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
NZ705848A (en) Anti-cd38 antibodies
CO6230999A2 (es) Anticuerpo anti-esclerostina
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
PE20091261A1 (es) Anticuerpos anti-hepcidina
JP2013542194A5 (enExample)
RU2015110981A (ru) Комбинации и их применение
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20170209

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2019 BY ANAQUA SERVICES

Effective date: 20180219

LAPS Patent lapsed